NRSN Neurosense Therapeutics Ltd
Company Analysis
Latest News
🔴 Neurosense Therapeutics is trading 7.06% down today amid concerns over Phase 3 funding delays
Neurosense Therapeutics is trading at $0.37 (-7.06%) amid broader biotech and market weakness; no confirmed August 20, 2026 company-specific announcement...
🔴 Neurosense Therapeutics is trading 10.97% down today; no specific catalyst confirmed
Neurosense Therapeutics is trading at $0.34, down -10.97%, with no specific catalyst confirmed. • No credible company-specific announcement dated August 19,...
🟢 Neurosense Therapeutics rises 7.3% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 Neurosense Therapeutics is trading 6.81% up in pre-market following continued after-hours strength despite no confirmed company-specific catalyst
Neurosense Therapeutics is trading now 6.81% up at $0.41 after closing at $0.38 on August 18, 2026, following continued after-hours strength without a...
🟢 Neurosense Therapeutics is trading 12% up in after-hours trading with no confirmed catalyst
Neurosense Therapeutics is trading at $0.43, up 12.02% in after-hours trading, with no confirmed company-specific catalyst. - It closed at $0.38 on August 18,...
🟢 Neurosense Therapeutics is trading 5% up in after-hours trading without a confirmed company catalyst
Neurosense Therapeutics is trading 5% up in after-hours trading at $0.40 after the August 18, 2026 close of $0.38, reflecting limited positioning rather than a...
🔴 Neurosense Therapeutics is trading 11% down today amid broad risk-off selling
Neurosense Therapeutics is trading 11% down at $0.39 amid broad risk-off selling on August 18, 2026. - Nasdaq Composite and S&P 500 fell as technology shares...
🔴 Neurosense Therapeutics is trading 5% down today amid a broader market pullback
Neurosense Therapeutics is trading 5% down at $0.41 amid a broader market pullback. - The S&P 500 was down 0.61% and the Nasdaq Composite was down 1.37% on...
🔴 Neurosense Therapeutics is trading 5% down today with no new company-specific catalyst identified
Neurosense Therapeutics is trading 5.10% down now at $0.43 after no new company-specific catalyst was identified on August 17, 2026. - The latest material...
🟢 Neurosense Therapeutics is trading 5.94% up today — catalyst remains unclear
Neurosense Therapeutics is trading 5.94% up at $0.48, with the catalyst unclear on August 17, 2026. - No new company-specific announcement has been...
🟢 Neurosense Therapeutics is trading 11.59% up in pre-market with no new company-specific announcement identified
Neurosense Therapeutics is trading 11.59% up at $0.51 in pre-market, with no new company-specific announcement identified for August 17, 2026, and the catalyst...
🟢 Neurosense Therapeutics is trading 6.44% up in after-hours trading
Neurosense Therapeutics is trading 6.44% up at $0.48 after no new company-specific announcement was identified for August 14, 2026. - An August 13 CEO letter...
NeuroSense's ALS Drug Funding Hits a Wall — Can a Sub-Dollar Stock Survive Nasdaq's Patience Running Out?
Shares of NeuroSense Therapeutics shifted sharply this week as a CEO letter dated August 13, 2026, laid bare the company's struggle to fund its most important...
🟢 Neurosense Therapeutics is trading 8.46% up today in after-hours trading after PARAGON ALS funding delays
Neurosense Therapeutics is trading 8.46% up at $0.48 after its August 13, 2026 CEO letter detailed delays securing funding for the Phase 3 PARAGON ALS study. -...
🔴 Neurosense Therapeutics is trading 5% down today after CEO letter highlighted funding delays
Neurosense Therapeutics is trading 5% down at $0.45 after its August 13, 2026 CEO letter highlighted delays securing funding for the Phase 3 PARAGON ALS...
🟢 Neurosense Therapeutics is trading 5% up in pre-market
Neurosense Therapeutics is trading at $0.49, up +5.08% in pre-market; the catalyst remains unclear and may reflect low-priced biotech trading activity. - No...
🟢 Neurosense Therapeutics is trading 5.4% up today with no confirmed company-specific catalyst
Neurosense Therapeutics is trading 5.4% up at $0.50, possibly reflecting broader risk-on sentiment, though the catalyst remains unconfirmed. - No fresh...
🔴 Neurosense Therapeutics is trading 5.25% down today
Neurosense Therapeutics is trading at $0.45, down 5.25%, with no fresh company-specific announcement found to clearly explain the decline. - Available...
🟢 Neurosense Therapeutics is trading 5.68% up today on PrimeC regulatory alignment
Neurosense Therapeutics is trading at $0.53, up 5.68%, after its August 6 announcement targeting a December 2026 Health Canada filing for PrimeC. - The...
NeuroSense Nears a Canadian Drug Filing for Its ALS Treatment — But Can an $18 Million Company Deliver on the Promise?
Shares of NeuroSense Therapeutics shifted sharply higher this week, touching $0.56 — up 7.5% from the prior close — after the micro-cap biotech announced it...